MDS Nordion and Macrocyclics Collaborate to Develop Bifunctional Chelates

MDS Nordion and Macrocyclics Inc. have announced a three-year research and development collaboration to develop innovative bifunctional chelates for use in molecular imaging and targeted therapeutic pharmaceuticals. This partnership aims to create novel chelate structures, linkers, and conjugation methods that will enable researchers to use a wider range of targeting vectors. The collaboration seeks to improve the efficiency of radiolabelling at room temperature, while maintaining stability comparable to industry-standard chelates.

Key Takeaways:

• The collaboration between MDS Nordion and Macrocyclics Inc. will focus on developing novel bifunctional chelates for use in molecular imaging and targeted therapeutic pharmaceuticals over a period of three years.
• The research will focus on creating new chelate structures, linkers, and conjugation methods to enable the use of a wider range of targeting vectors by the research community.
• The objective is to develop and make available chelates with performance features such as high efficiency radiolabelling at room temperature and stability comparable to industry-standard chelates.
• The collaboration will utilize various MDS Nordion radioisotopes, including yttrium-90, lutetium-177, indium-111, and copper-64, to assess the new chelates.
• Molecular imaging and targeted therapeutic pharmaceuticals are increasingly being used in the drug development process to diagnose and treat diseases, including cancer.
• Researchers will have access to bifunctional chelates and linkers, enabling them to pursue new avenues of investigation for the diagnosis and treatment of disease.

Statistics:

• The collaboration will last for three years.
• The research will focus on developing novel chelate structures, linkers, and conjugation methods.
• The collaboration will utilize multiple radioisotopes, including yttrium-90, lutetium-177, indium-111, and copper-64.
• The new chelates will be assessed for performance features such as high efficiency radiolabelling at room temperature and stability comparable to industry-standard chelates.
• The partnership aims to improve the efficiency and effectiveness of molecular imaging and targeted therapeutic pharmaceuticals.

Sources:

• Health & Medicine Week editors, "MDS Nordion and Macrocyclics Inc. announce research and development collaboration, issued 2005, via NewsRx.com.